Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Separation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN107382875A offers high-purity Rosuvastatin Impurity B synthesis with significant yield improvements and simplified processing for reliable pharmaceutical intermediates supplier partnerships.
Patent CN114262270B reveals a scalable synthesis of aryl dihydronaphthalene lignans with potent HeLa inhibition, offering a reliable supply chain for oncology intermediates.
Patent CN104945468A reveals a metal-free route for MMAF impurities. This method ensures high purity and supply chain stability for ADC manufacturing.
Patent CN110467539B reveals a cost-effective dynamic kinetic resolution for 2,6-dimethyl-L-tyrosine, eliminating noble metals and enhancing supply chain stability for peptide manufacturers.
Advanced purification patent CN103467310B ensures high purity chiral intermediate for Linezolid and Rivaroxaban with scalable manufacturing capabilities.
Patent CN1989093A details a scalable diastereomeric resolution method for spirobiindane derivatives, offering cost reduction and high purity for liquid crystal and polymer applications.
Novel thienopyrimidine synthesis patent CN108424417B offers enhanced Mcl-1 inhibition. Reliable supplier for high-purity pharmaceutical intermediates with scalable processes.
Patent CN105399644A reveals novel chiral recognition compounds enabling high-purity separation. This process offers substantial cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Novel (-)-enantiomer synthesis offers superior PPAR activation. Reliable supply chain for metabolic disorder intermediates with optimized purity.
Novel sulfonation resolution method for dexmedetomidine intermediate ensures high yield and purity for pharmaceutical supply chains.
Patent CN103524360B details a novel zinc powder reduction route for S 16257-2 intermediate, offering enhanced purity and supply chain stability for global pharmaceutical manufacturers.
Patent CN113185439B reveals scalable chiral ligand synthesis reducing costs and enhancing supply chain reliability for complex pharmaceutical manufacturing processes.
Patent CN101838282B details a cost-effective resolution method for 4-AA, avoiding expensive catalysts for reliable pharmaceutical intermediate supply.
Patent CN115197115A details a novel chiral synthesis route offering high optical purity and scalable manufacturing for pharmaceutical intermediates and cost reduction.
Eliminate chiral column costs with novel crystallization-based resolution. Achieve >99% ee and 76-78% yield for 6,6'-dihydroxy-5,5'-bisquinoline. Scale to 100MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.